Gujarat Magazine

DelveInsight’s ‘Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Key Takeaways from the Age-related Macular Degeneration Market Report

• The increase in Age-related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Age-related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR.
• The leading Age-related Macular Degeneration Companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
• Promising Age-related Macular Degeneration Therapies in the various stages of development include Anecortave Acetate 15 mg sterile suspension, Triamcinolone Acetate 4 mg, rhuFab V2 (ranibizumab), NG101 AAV gene therapy, Intravitreal Aflibercept Injection, and others.
• May 2024:- Neuracle Genetics Inc.- This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
• January 2024:- Acer Medical Inc.- An observational study is designed to evaluate the clinical performance of VeriSee AMD for potential age-related macular degeneration (AMD) screening from color fundus photography images. The sensitivity and specificity of VeriSee AMD’s automated image analysis for screening AMD will be determined through the comparison with the gold standard, which is the judgment of AMD by the ophthalmologists.
• January 2024:- i-Lumen Scientific, Inc.- Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD). The i-Lumen(TM) AMD device is for in-office therapy use to deliver microcurrent electrical stimulation transpalpebrally (via the eyelid) for use by an ophthalmologist. The i-Lumen AMD device contains proprietary software with preset treatment algorithms and is calibrated at each session to the individual participant.

 

Discover which therapies are expected to grab the Age-related Macular Degeneration Market Share @ Age-related Macular Degeneration Market Outlook

 

Age-related Macular Degeneration Overview

Age-related macular degeneration (AMD) is a common eye condition that affects the macula, which is the central part of the retina responsible for sharp, central vision needed for activities like reading and driving. AMD typically occurs in older adults and gradually worsens over time, leading to a loss of central vision. There are two main types of AMD: dry AMD, which involves the breakdown of light-sensitive cells in the macula, and wet AMD, which involves the growth of abnormal blood vessels underneath the macula.

 

Age-related Macular Degeneration Epidemiology Insights

The epidemiology section of Age-related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Age-related Macular Degeneration Epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights

 

Age-related Macular Degeneration Drugs Market

The Age-related Macular Degeneration Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Age-related Macular Degeneration signaling in Age-related Macular Degeneration are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Age-related Macular Degeneration Treatment Market Landscape

The Age-related Macular Degeneration treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Age-related Macular Degeneration has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To learn more about Age-related Macular Degeneration treatment guidelines, visit @ Age-related Macular Degeneration Treatment Market Landscape

 

Age-related Macular Degeneration Market Outlook

The report’s outlook on the Age-related Macular Degeneration market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Age-related Macular Degeneration therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Age-related Macular Degeneration drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Age-related Macular Degeneration market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Age-related Macular Degeneration Drugs Uptake

The drug chapter of the Age-related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Age-related Macular Degeneration.

 

Major Age-related Macular Degeneration Companies

Several Age-related Macular Degeneration Companies working in the market include Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.

 

Learn more about the FDA-approved drugs for Age-related Macular Degeneration @ Drugs for Age-related Macular Degeneration Treatment

 

Scope of the Age-related Macular Degeneration Market Report

• Coverage- 7MM
• Age-related Macular Degeneration Companies- Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA In, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics and others.
• Age-related Macular Degeneration Therapies- Anecortave Acetate 15 mg sterile suspension, Triamcinolone Acetate 4 mg, rhuFab V2 (ranibizumab), NG101 AAV gene therapy, Intravitreal Aflibercept Injection, and others.
• Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market Drivers and Barriers
• Age-related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Age-related Macular Degeneration Drugs in development @ Age-related Macular Degeneration Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders’ Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/